Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | PPARD | Q03181 | 4/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 5/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10004551 | 1.00 | PPARG (0.48) | PPARGPPARDALOX5ACLYNOD2 | |
| SCHEMBL10003730 | 0.92 | ALOX5 (0.43) | PPARGPPARDALOX5ACLYNOD2 | |
| SCHEMBL10003732 | 0.92 | ALOX5 (0.43) | PPARGPPARDALOX5ACLYNOD2 | |
| SCHEMBL10002909 | 0.89 | ALOX5 (0.42) | PPARGPPARDALOX5ACLYNOD2 | |
| SCHEMBL10002907 | 0.89 | ALOX5 (0.42) | PPARGPPARDALOX5ACLYNOD2 | |
| SCHEMBL10003661 | 0.89 | ALOX5 (0.43) | PPARGPPARDALOX5NOD2NOD1 | |
| SCHEMBL10003655 | 0.89 | ALOX5 (0.43) | PPARGPPARDALOX5NOD2NOD1 | |
| SCHEMBL16792452 | 0.87 | ALOX5 (0.58) | ALOX5NOD2NOD1LMNARAB9A | |
| SCHEMBL16792457 | 0.87 | ALOX5 (0.58) | ALOX5NOD2NOD1LMNARAB9A | |
| SCHEMBL16792454 | 0.87 | ALOX5 (0.58) | ALOX5NOD2NOD1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471786-B1 | AMINOPYRAZOLE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2471786-A1 | AMINOPYRAZOLE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208811-A1 | Aminopyrazole Derivative | FGFR1, FGFR3, FGFR4 | PPARG 1775/4885PPARD 2256/4885ALOX5 2600/4885 |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, CYP3A43 | PPARG 2257/4885PPARD 3399/4885ALOX5 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.